Key result
APOA5 TT-1131 genotype linked to ~6-point greater statin-induced LDL-C reduction vs C allele carriers.
Cohort (n=187)
Answers are grounded in this paper and cite their sources.
AIMS: Despite the fact that statin treatment efficacy is very high, there are substantial differences in treatment effectiveness among individuals. It is supposed that genetic predisposition plays an important role in these differences, but the contribution of individual polymorphisms is poorly understood. So far, more than 30 genes have been examined with ambiguous results. Apolipoprotein A5 is an important determinant of plasma lipid concentrations and its genetic variation could account for some of the observed differences in the response to statin therapy. However, this has not been analyzed before. MATERIALS AND METHODS: We examined the putative association between APOA5 SNPs (c.-1131T>C, c.56C>G and c.457G>A) and efficacy during 3 months of statin treatment in 187 adult Caucasians. Patients were treated with low-dose (10 or 20 mg per day) simvastatin (46.3%), atorvastatin (40.5%) and lovastatin (13.2%). RESULTS: The decrease in cholesterol was not significantly associated with the type or dose of statin. Carriers of the APOA5 genotype TT-1131 (n = 154) benefited more from statin treatment when compared with the C-1131 allele carriers (n = 33) (Delta low-density lipoprotein cholesterol: -36.3 +/- 15.1% vs Delta low-density lipoprotein cholesterol: -29.9 +/- 12.5%; p < 0.005, Mann-Whitney test). This result was independent of sex, age, BMI and APOE polymorphism. CONCLUSION: Our results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment.
No takes yet. Share an insight, caveat, or question.
Hubáček et al. (2009) conducted a cohort in Patients on statin treatment (n=187). APOA5 genotype TT-1131 vs. APOA5 C-1131 allele carriers was evaluated on Change in low-density lipoprotein cholesterol (Delta LDL-C) (p=<0.005). Carriers of the APOA5 genotype TT-1131 had a greater reduction in LDL cholesterol after 3 months of statin therapy compared to C-1131 allele carriers.
Synapse has enriched 10 related papers. Consider them for comparative context: